EMA Authorised: NexoBrid (proteolytic enzymes enriched in bromelain) — MediWound Germany GmbH

View source ↗

Summary

EMA has authorised NexoBrid, a bromelain-based proteolytic enzyme product, for debridement in burn wounds. The approval is granted to MediWound Germany GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burns

Drugs mentioned

• NEXOBRID (ANACAULASE-BCDB)

Snippet

Status: Authorised. Therapeutic area: Debridement. MAH: MediWound Germany GmbH. Decision date: 03/12/2025